Blazing a Trail in Ph-ALL: Chemotherapy‑Free Options Gain Ground

Cancer research · Acute lymphoblastic leukemia

Chemotherapy‑free regimens such as ponatinib plus reduced‑intensity chemotherapy, dasatinib with blinatumomab, or ponatinib with blinatumomab are achieving high remission rates and roughly 80% four‑year survival in Philadelphia chromosome‑positive acute lymphoblastic leukemia.

This article reviews recent advances in treating Philadelphia chromosome‑positive (Ph‑ALL) acute lymphoblastic leukemia (ALL), highlighting the shift from intensive chemotherapy to chemotherapy‑free regimens. Phase‑3 data from the PhaLLCON trial (NCT03589326) show ponatinib plus reduced‑intensity chemotherapy yields a higher MRD‑negative complete remission rate (34.4% vs. 16.7% for imatinib). The GIMEMA LAL2116 (D‑ALBA) trial demonstrated a 96.5% complete hematologic response rate with dasatinib and blinatumomab induction and consolidation. Early results from the American Society of Hematology conference report ponatinib combined with blinatumomab achieving durable MRD negativity. These studies suggest that chemotherapy‑free strategies can provide effective disease control and improve long‑term survival, potentially redefining frontline treatment for Ph‑ALL.

Achieving high remission and survival rates without chemotherapy can reduce treatment toxicity, improve quality of life, and challenge the need for allogeneic transplant and other intensive therapies in this historically aggressive leukemia subtype.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals